Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas.
NGS
PMBL
molecular pathology
next generation sequencing
primary mediastinal large B-cell lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
08
09
2023
accepted:
03
10
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Since the description of primary mediastinal large B-cell lymphoma (PMBL) as a distinct entity from diffuse large B-cell lymphomas (DLBCL), numerous studies have made it possible to improve their definition. Despite this, this differential diagnosis can be challenging in daily practice. However, in some centers, PMBL may be treated according to a particular regimen, distinct from those used in DLBCL, emphasizing the importance of accurate identification at diagnosis. This study aimed to describe the histological and molecular characteristics of PMBL to improve the accuracy of their diagnosis. Forty-nine cases of PMBL were retrospectively retrieved. The mean age at diagnosis was 39 years (21-83), with a sex ratio of 0.88. All cases presented a fibrous background with diffuse growth of intermediate to large cells with an eosinophil (26/49, 53%) or retracted cytoplasm (23/49, 47%). "Hodgkin-like" cells were observed in 65% of cases (32/49, 65%). The phenotype was: BCL6+ (47/49, 96%), MUM1+ (40/49, 82%), CD30+ (43/49, 88%), and CD23+ (37/49, 75%). Genomic DNAs were tested by next generation sequencing of 33 cases using a custom design panel. Pathogenic variants were found in all cases. The most frequent mutations were:
Identifiants
pubmed: 37835560
pii: cancers15194866
doi: 10.3390/cancers15194866
pmc: PMC10571533
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Haematol. 2021 Jun;193(6):1110-1122
pubmed: 33764507
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567641
Blood Cancer J. 2021 May 21;11(5):100
pubmed: 34021121
Nature. 2011 Mar 17;471(7338):377-81
pubmed: 21368758
Cell Rep. 2015 Nov 17;13(7):1418-1431
pubmed: 26549456
Ann Transl Med. 2021 Jun;9(12):1037
pubmed: 34277837
Blood Cancer J. 2020 Jun 17;10(6):69
pubmed: 32555149
Front Oncol. 2021 Mar 22;11:654854
pubmed: 33869061
J Clin Oncol. 2017 Jun 20;35(18):2008-2017
pubmed: 28459613
Blood. 2015 Jan 22;125(4):668-79
pubmed: 25428220
Br J Haematol. 2019 Dec;187(5):627-637
pubmed: 31407320
Pathol Res Pract. 2022 Jan;229:153697
pubmed: 34839096
Mod Pathol. 2020 May;33(5):834-845
pubmed: 31822802
Leukemia. 2008 Nov;22(11):2106-10
pubmed: 18401415
Immunol Res. 2011 May;50(1):87-96
pubmed: 21442426
Blood. 2021 Jul 15;138(2):136-148
pubmed: 33684939
Blood. 2018 Nov 29;132(22):2401-2405
pubmed: 30257882
Blood. 2019 Sep 5;134(10):802-813
pubmed: 31292115
Blood. 2015 Jan 1;125(1):33-9
pubmed: 25499450
Leuk Lymphoma. 2004 Oct;45(10):2105-10
pubmed: 15370257
Adv Anat Pathol. 2004 Sep;11(5):227-38
pubmed: 15322489
Int J Hematol Oncol Stem Cell Res. 2022 Apr 1;16(2):94-102
pubmed: 36304730
J Mol Diagn. 2017 May;19(3):341-365
pubmed: 28341590
Blood. 2021 Apr 1;137(13):1765-1776
pubmed: 32961552
Ther Adv Hematol. 2021 Oct 8;12:20406207211048959
pubmed: 34659697
Blood. 2018 Aug 23;132(8):865-867
pubmed: 29866812
Nat Commun. 2022 Sep 6;13(1):4487
pubmed: 36068219
Nat Genet. 2014 Apr;46(4):329-35
pubmed: 24531327
Blood. 2018 May 31;131(22):2454-2465
pubmed: 29650799
Leuk Lymphoma. 2011 Aug;52(8):1495-503
pubmed: 21623692
Sci Rep. 2022 Jun 22;12(1):10551
pubmed: 35732790
Med Mol Morphol. 2020 Jun;53(2):124-129
pubmed: 31728727
iScience. 2021 Dec 20;25(1):103668
pubmed: 35036866
Am J Surg Pathol. 1996 Jul;20(7):877-88
pubmed: 8669537
Blood. 2009 Aug 6;114(6):1236-42
pubmed: 19423726
Blood Adv. 2020 Jun 9;4(11):2523-2535
pubmed: 32516416
Am J Surg Pathol. 2022 Jan 1;46(1):58-70
pubmed: 34265801
Oncogene. 2006 Apr 27;25(18):2679-84
pubmed: 16532038
Blood Adv. 2021 Aug 24;5(16):3227-3239
pubmed: 34427583
Oncotarget. 2015 Oct 6;6(30):29097-110
pubmed: 26336985
J Mol Diagn. 2017 Nov;19(6):892-904
pubmed: 29054399
Zhonghua Bing Li Xue Za Zhi. 2021 Oct 8;50(10):1139-1144
pubmed: 34619867
Blood. 2003 Dec 1;102(12):3871-9
pubmed: 12933571
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e865-e875
pubmed: 34330673
Blood Adv. 2021 Oct 12;5(19):3862-3872
pubmed: 34461634
Int J Surg Pathol. 2010 Apr;18(2):121-8
pubmed: 19223373
Mod Pathol. 2012 Dec;25(12):1637-43
pubmed: 22899296
Am J Pathol. 2003 Jan;162(1):243-53
pubmed: 12507907
Am J Clin Pathol. 2021 Sep 8;156(4):497-512
pubmed: 34398178
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Pathology. 2020 Jan;52(1):53-67
pubmed: 31735345
Hemasphere. 2018 Dec 27;3(1):e169
pubmed: 31723808
Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):725-730
pubmed: 31789821
Blood Adv. 2020 Nov 24;4(22):5652-5665
pubmed: 33211828
EClinicalMedicine. 2022 Oct 01;54:101674
pubmed: 36204003
Am J Clin Pathol. 2016 May;145(5):710-6
pubmed: 27124935
Clin Cancer Res. 2016 Jun 15;22(12):2919-28
pubmed: 26819451
Leuk Res. 2000 Apr;24(4):331-7
pubmed: 10713330
J Exp Med. 2003 Sep 15;198(6):851-62
pubmed: 12975453
Histopathology. 2017 Jul;71(1):89-97
pubmed: 28231401
Blood. 2004 Jul 15;104(2):543-9
pubmed: 15044251